Dual-AntiPlatelet Therapy strategies FOR elective PCI in a REAL-world setting

Recruiting

Conditions: Coronary artery disease
10011082

Registration Number: NL-OMON51842

Lead Sponsor: Amsterdam UMC

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 1462

Inclusion Criteria

- Adult men and women aged at least 18 years
- Scheduled for diagnostic CAG due to suspected obstructive coronary artery
disease

Exclusion Criteria

- Inability to give informed consent (e.g., language barrier)
- Presence of contra-indications for the use of clopidogrel
- Patients using clopidogrel for other reasons than the scheduled diagnostic
CAG
- Patients using P2Y12 inhibitors other than clopidogrel
- Patients using VKA
- Patients using DOAC/NOAC

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The difference in occurrence of the composite endpoint 'Net Adverse Clinical<br /><br>Events' (NACE; all-cause death, myocardial infarction, definite/probable stent<br /><br>thrombosis, stroke and BARC type 2, -3 or -5 bleeding) assessed at 30 days. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To assess the difference in :<br /><br>- Bleeding Academic Research Consortium (BARC) -2, -3 and -5 bleeding<br /><br>in-hospital and at 30 days<br /><br>- The composite endpoint 'Patient Oriented Clinical Events' (POCE; all-cause<br /><br>death, stroke, myocardial infarction, repeat revascularization) in-hospital and<br /><br>at 30 days<br /><br>- Individual endpoints of the composite endpoints POCE / NACE in-hospital and<br /><br>at 30 days</p><br>